biomarkers

Many are probably already familiar with “Biomarkers”. This is a term usually used to describe a molecule or gene that indicates a change in a person’s health or risk of disease. As technology take’s its innovative course in healthcare, Biomarkers are going digital. Digital tools, such as smartphones, wearables and fitness trackers, continually collect health data from users. This information can offer actionable insights into the biological state of the individual, potentially offering opportunities to change behaviours or initiate treatments that can improve outcomes. I believe that Digital Biomarkers are the future of precision medicine and is offering real-world evidence of patient outcomes. This evolution is fuelled by the transition to value-based healthcare. Incentives are aligning to support continuous, proactive care across the healthcare industry. To unlock the full potential of Digital Biomarkers, it is vital that we leverage digital medicine, genomics, data science, informatics, and artificial intelligence, while tracking symptoms of disease progression, and medication adherence. Transforming this data into actionable insights can drive measurable results, and accurately predict outcomes of treatment. Real-World Value Regulators and payers are increasingly interested in the insights yielded by Digital Biomarkers. From their perspective, they can generate meaningful evidence of safety and efficacy, support marketing claims and inform reviews of clinical utility and value. Through extensive research, I have seen critical advances in machine learning, artificial intelligence, algorithm development, and statistical data modelling, which can identify useful digital surrogates. Specifically, a sub-field of machine learning has emerged with algorithms that have unprecedented representational power and the ability to discover patterns that humans are unable to find or describe. These techniques have the ability to monitor and predict personalized health outcomes for individual patients, as well as overall trends of health and disease states for patient populations. As with traditional Biomarkers, my experience is...